High yields of stable and highly pure nucleocapsid proteins of different hantaviruses can be generated in the yeast Saccharomyces cerevisiae

Institute of Biotechnology, V. Graiciuno 8, LT-2028 Vilnius, Lithuania.
Journal of Biotechnology (Impact Factor: 2.87). 09/2004; 111(3):319-33. DOI: 10.1016/j.jbiotec.2004.04.010
Source: PubMed


Recently, the high-level expression of authentic and hexahistidine (His)-tagged Puumala (strain Vranica/Hällnäs) hantavirus nucleocapsid protein derivatives in the yeast Saccharomyces cerevisiae has been reported [Dargeviciute et al., Vaccine, 20 (2002) 3523-3531]. Here we describe the expression of His-tagged nucleocapsid proteins of other Puumala virus strains (Sotkamo, Kazan) as well as Dobrava (strains Slovenia and Slovakia) and Hantaan (strain Fojnica) hantaviruses using the same system. All nucleocapsid proteins were expressed in the yeast S. cerevisiae at high levels. The nucleocapsid proteins can be easily purified by nickel chelate chromatography; the yield for all nucleocapsid proteins ranged from 0.5 to 1.5 mg per g wet weight of yeast cells. In general, long-term storage of all nucleocapsid proteins without degradation can be obtained by storage in PBS at -20 degrees C or lyophilization. The nucleocapsid protein of Puumala virus (strain Vranica/Hällnäs) was demonstrated to contain only traces of less than 10 pg nucleic acid contamination per 100 microg of protein. The yeast-expressed nucleocapsid proteins of Hantaan, Puumala and Dobrava viruses described here represent useful tools for serological hantavirus diagnostics and for vaccine development.

Download full-text


Available from: Jonas Schmidt-Chanasit,
  • Source
    • "To express the N protein of SBV virus, we exploited yeast vector system previously used for the high-level expression of hantaviruses N proteins [17]. Expression efficiency of recombinant SBV N protein in yeast was proven both by electrophoresis and immunoblotting. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Schmallenberg virus (SBV), discovered in continental Europe in late 2011, causes mild clinical signs in adult ruminants, including diarrhoea and reduced milk yield. However, fetal infection can lead to severe malformation in newborn offspring. To develop improved reagents for SBV serology, a high-level yeast expression system was employed to produce recombinant SBV nucleocapsid (N) protein. Recombinant SBV N protein was investigated as an antigen in SBV-specific IgG enzyme immunoassay and used for generation of monoclonal antibodies (MAbs). Yeast-expressed SBV N protein was reactive with anti-SBV IgG-positive cow serum specimens collected from different farms of Lithuania. After immunization of mice with recombinant SBV N protein, four MAbs were generated. The MAbs raised against recombinant SBV N protein reacted with native viral nucleocapsids in SBV-infected BHK cells by immunofluorescence assay. The reactivity of recombinant N protein with SBV-positive cow serum specimens and the ability of the MAbs to recognize virus-infected cells confirm the antigenic similarity between yeast-expressed SBV N protein and native viral nucleocapsids. Our study demonstrates that yeast expression system is suitable for high-level production of recombinant SBV N protein and provides the first evidence on the presence of SBV-specific antibodies in cow serum specimens collected in Lithuania.
    Journal of Immunology Research 05/2014; 2014:160316. DOI:10.1155/2014/160316 · 2.93 Impact Factor
  • Source
    • "Many expression systems have been developed for genetically engineering vaccines of HTNV like the yeast expression system [41], E. coli expression system [37], mammalian expression system [42], insect virus expression system [19], the adenovirus expression system [10], and others. In many expression systems, Ad5-based vectors have been extensively applied because they permit the introduction of relatively large DNA sequences, are safe to use and do not integrate into the host genome, are easy to construct and propagate, and can effectively present antigen and induce humoral and cellular immune responses. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Heat shock proteins (HSPs) display adjuvant functions when given as fusion proteins to enhance vaccination efficiency. To evaluate enhanced potency of Hantaan virus (HTNV) glycoprotein (GP) and nucleocapsid protein (NP) immunogenicity by heat shock protein 70 (HSP70), a recombinant adenovirus rAd-GnS0.7-pCAG-HSP70C expression vector was developed by genetically linking the HSP70 C-terminal gene (HSP70 359-610 aa, HSP70C) to the Gn and 0.7 kb fragment of the NP (aa1-274-S0.7). C57BL/6 mice were immunized with these recombinant adenoviral vectors. A series of immunological assays determined the immunogenicity of the recombinant adenoviral vectors. The results showed that rAd-GnS0.7-pCAG-HSP70C induced a stronger humoral and cellular immune response than other recombinant adenoviruses (rAd-GnS0.7-pCAG and rAd-GnS0.7) and the HFRS vaccine control. Animal protection experiments showed that rAd-GnS0.7-pCAG-HSP70C was effective at protecting C57BL/6 mice from HTNV infection. The results of the immunological experiments showed that HSP70C lead to enhanced vaccine potency, and suggested significant potential in the development of genetically engineered vaccines against HTNV.
    PLoS ONE 02/2014; 9(2):e88183. DOI:10.1371/journal.pone.0088183 · 3.23 Impact Factor
  • Source
    • "The gene fragments encoding different polypeptides of hMPV N were subcloned into pFX7-6His (Razanskiene et al., 2004) by using plasmid hMPV N pFX7 as the template for the PCRs, resulting in plasmids pFX7-6His-hMPV N (90–395), pFX7-6His-hMPV N (1–365), pFX7-6His-hMPV N (1–335), pFX7-6His-hMPV N (1–305), pFX7-6His-hMPV N (1–275) and pFX7-6His-hMPV N (1–245). The primer pairs used were: 90-F and 395-R to amplify the hMPV N (90–395) construct, 1-F and 365-R to amplify the hMPV N (1–365) construct, 1-F and 335-R to amplify the hMPV N (1–335) construct, 1-F and 305-R to amplify the hMPV N (1–305) construct, 1-F and 275-R to amplify the hMPV N (1–275) construct, and 1-F and 245-R to amplify the hMPV N (1–245) construct. "

    New Biotechnology 09/2009; 25. DOI:10.1016/j.nbt.2009.06.071 · 2.90 Impact Factor
Show more